Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
Want to see SGMT full AI Analyst Report?
SGMT Stock Chart & Stats
$6.47
-$0.58(-10.41%)
At close: 4:00 PM EST
$6.47
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$3.08 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)365.43K
Market Cap
$465.61M
Enterprise Value$240.41M
Total Cash (Recent Filing)$113.12M
Total Debt (Recent Filing)$78.00K
Price to Earnings (P/E)―
Beta2.83
Next Earnings
May 20, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding61,184,315
10 Day Avg. Volume392,336
30 Day Avg. Volume365,426
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.23
Forecast
1Y Price Target
$25.11Price Target Upside288.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.44
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Acne Franchise And Regulatory MilestonesProgress with the next‑generation FASN inhibitor TVB‑3567 and regulatory acceptance of denifanstat in Asia create multiple paths for clinical validation and potential milestone and royalty revenues that could materially add commercial value.
Clinical Development StrategyPharmacokinetic and safety data for the denifanstat–resmetirom combination support advancing into a Phase 2 proof‑of‑concept study in advanced liver fibrosis with a plan to use non‑invasive tests as primary endpoints to simplify enrollment and assessments.
Mechanism Of ActionDenifanstat inhibits fatty acid synthase to address the root biological drivers of acne rather than only reducing oil, giving the drug a clearly differentiated mechanism that supports stronger clinical potential.
Bears Say
Analyst Conflict Of InterestDisclosure that the reporting firm does and seeks to do business with covered companies creates a potential conflict that could undermine perceived objectivity of analyst reports and influence investor interpretation of research.
Financing RiskCurrent cash resources suggest a limited runway that could require additional financing to fully advance the clinical programs, raising dilution and execution risk concerns for shareholders.
Market Sentiment And ValuationMarket appears to underappreciate both the lead liver program and the acne franchise, which could keep the stock’s valuation depressed despite clinical and regulatory progress.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $3.08 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $465.61M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is May 20, 2026 which is in 16 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Mar 11, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.432 by $0.142.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.38.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 61,184,315 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.432. Following the earnings report the stock price went up 3.797%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.11 (288.12% Upside)
$25.11 (288.12% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 549.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
192.76%
12-Months-Change
Fundamentals
Return on Equity
-40.85%
Trailing 12-Months
Asset Growth
-27.32%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$25.11
▲(288.12% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
5.49% Insiders
3.12% Mutual Funds
0.46% Other Institutional Investors
88.37% Public Companies and
Individual Investors